Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug
Investigators on the drug say that Ganymed’s IMAB362 “can significantly extend median survival when added to standard chemotherapy–13.2 months vs. 8.4 months–for... Read More
Day
